focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSeneca Growth Regulatory News (HYG)

Share Price Information for Seneca Growth (HYG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 13.50
Bid: 10.00
Ask: 17.00
Change: 0.00 (0.00%)
Spread: 7.00 (70.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 13.50
HYG Live PriceLast checked at -
Seneca Growth Capital VCT is an Investment Trust

To provide shareholders with an attractive income and capital return by investing its funds in a portfolio of both unquoted and quoted UK MedTech companies which meet the relevant criteria under the VCT Rules.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Net Asset Value(s)

4 Apr 2024 07:00

Net Asset Value(s)

Net Asset Value(s)

Seneca Growth Capital VCT Plc (the "Company")

4 April 2024

Net asset value (“NAV”)

The Directors and the Investment Manager of the Company, Seneca Partners Limited (“Seneca”), have reviewed the valuation of the Company’s Ordinary and B share investment portfolios and announce an updated NAV for each of the share classes as at 31 March 2024.

B Shares

As at 31 March 2024, the unaudited NAV per B share was 63.7p.

This is a decrease of 7.0p from the audited NAV as at 31 December 2023 of 70.7p, predominantly as a result of AIM market volatility. The B share NAV as at 31 March 2024 incorporates changes in the bid prices of the B share pool’s AIM/AQSE quoted investments combined with the impact of income receivable and running costs incurred in the period. There have been no material changes in the valuations of any of the unlisted investments during the period from 31 December 2023 to the date of this announcement.

The unaudited NAV total return per B share (NAV plus cumulative dividends) as at 31 March 2024 was 78.7p.

Ordinary Shares

As at 31 March 2024, the unaudited NAV of an Ordinary share was 16.8p per share.

This is a decrease of 1.7p from the audited NAV as at 31 December 2023 of 18.5p and is principally due to a reduction in the value of the Ordinary share pool’s investment in AIM quoted Scancell Holdings Plc and a decrease in the Ordinary share pool’s investment in AIM quoted Arecor Therapeutics Plc. As at 31 March 2024, shares in Scancell Holdings Plc were valued at 10.0p per share (31 December 2023: 10.5p) and shares in Arecor Therapeutics Plc were valued at 135.0p per share (31 December 2023: 180p). The Directors also reviewed the unquoted investments held in the Ordinary share portfolio and concluded that no changes were required to the carrying value of those investments.

The unaudited NAV total return per Ordinary share (NAV plus cumulative dividends) as at 31 March 2024 was 90.1p.

The change in NAV for both the B Shares and Ordinary Shares represents a decrease of 0.1p per share, respectively, on the unaudited NAVs as at 20 March 2024, announced on 22 March 2024 and which was included in the Supplementary Prospectus published by the Company on 28 March 2024.

For the purposes of calculating the unaudited net asset value per share for both share classes, quoted investments are carried at closing bid prices as at 31 March 2024 and unquoted investments are carried at fair value as at 31 March 2024.

The number of B shares in issue at 31 March 2024 was 21,780,329 and the number of Ordinary shares was 8,115,376. Therefore, the total number of voting rights in the Company is 29,895,705.

The B share Offer by the Company remains open for the 2023/24 tax year until midday today, 4 April 2024 and shares will be allotted at the above latest published B share NAV.

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

For further information, please contact:

John Hustler, Seneca Growth Capital VCT Plc at john.hustler@btconnect.com

Richard Manley, Seneca Growth Capital VCT Plc at Richard.Manley@senecapartners.co.uk

Any enquiries regarding the offer for subscription of B shares should be directed to:

Matt Currie at Seneca Partners Limited on 01942 295 981 or at Matt.Currie@senecapartners.co.uk

Date   Source Headline
3rd Apr 20202:10 pmGNWIssue of Equity
31st Mar 20205:30 pmGNWNet Asset Value(s)
26th Mar 20204:31 pmGNWAGM Venue Change
13th Mar 20204:14 pmGNWInterim Dividend
10th Mar 20202:28 pmGNWIssue of Equity
10th Mar 20207:00 amGNWB Share Net Asset Value
3rd Mar 20204:30 pmGNWIssue of Supplementary Prospectus
27th Feb 20207:00 amGNWFinal Results
9th Dec 20195:45 pmGNWDirectorate Change
27th Nov 20192:45 pmGNWIssue of Equity
20th Nov 20194:00 pmGNWDuplicate: Second Interim Dividend
28th Oct 20197:00 amGNWSecond interim dividend
10th Oct 20196:30 pmGNWDirector/PDMR Shareholding
8th Oct 20191:55 pmGNWIssue of Equity
8th Oct 20197:00 amGNWUpdate for the quarter ended 30 September 2019
17th Jul 20198:00 amGNWCorrection: Offer for Subscription
16th Jul 20195:27 pmGNWOffer for Subscription
10th Jul 20195:20 pmGNWHalf-year report
18th Jun 20199:16 amRNSHolding(s) in Company
10th Jun 20196:14 pmRNSResult of AGM
16th May 20197:00 amRNSSecond Interim Dividend
29th Apr 20198:52 amRNSFinal Results
25th Apr 20197:00 amRNSNet Asset Value(s)
5th Apr 201912:47 pmRNSIssue of Equity
3rd Apr 201912:46 pmRNSIssue of Equity
29th Mar 20195:20 pmRNSRevised timetable
13th Mar 201912:03 pmRNSExtension of Offer
7th Mar 20193:22 pmRNSIssue of Equity
6th Mar 201910:30 amRNSInterim Dividend
6th Mar 20198:39 amRNSNet Asset Value(s)
28th Dec 20187:00 amRNSDividend Declaration
19th Dec 20182:21 pmRNSIssue of Equity
18th Dec 20189:56 amRNSUpdate on Hallmarq
17th Dec 20184:43 pmRNSReduction of Capital
29th Nov 20181:53 pmRNSHolding(s) in Company
23rd Nov 20187:00 amRNSUpdate for the quarter ended 30 September 2018
27th Sep 201810:59 amRNSIssue of Equity
23rd Apr 201812:43 pmRNSHolding(s) in Company
22nd May 201712:59 pmRNSHolding(s) in Company
24th Feb 201610:42 amRNSScancell to present at Biotech Capital
16th Feb 20159:47 amRNSHoldings in Company
24th Oct 20133:53 pmRNSInterim Management Statement
22nd Mar 20127:00 amRNSFinal Results
29th Oct 201011:18 amRNSInterim Management Statement
7th Sep 201011:34 amRNSDirector's Dealings
5th Aug 20107:00 amRNSHalf Yearly Report
7th May 20107:00 amRNSResults of AGM and IMS to 31 March 2010
31st Mar 20104:48 pmRNSAnnual Financial Report
22nd Jan 201012:26 pmRNSDeclaration of Interim Dividend
24th Sep 20099:43 amRNSDirector's Dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.